JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

Search

Twist Bioscience Corp

Closed

SectorHealthcare

56.4 -4.03

Overview

Share price change

24h

Current

Min

55.97

Max

58.77

Key metrics

By Trading Economics

Income

-3.4M

-31M

Sales

4.7M

104M

Profit margin

-29.419

Employees

979

EBITDA

-3.2M

-24M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

-7.35% downside

Dividends

By Dow Jones

Next Earnings

4 May 2026

Market Stats

By TradingEconomics

Market Cap

1.1B

3.7B

Previous open

60.43

Previous close

56.4

News Sentiment

By Acuity

50%

50%

201 / 348 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

29 Apr 2026, 23:53 UTC

Earnings

Naver Posts Weaker First-Quarter Earnings

29 Apr 2026, 23:41 UTC

Hot Stocks

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 Apr 2026, 23:55 UTC

Earnings

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 Apr 2026, 23:54 UTC

Earnings

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 Apr 2026, 23:52 UTC

Earnings

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 Apr 2026, 23:51 UTC

Earnings

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 Apr 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 Apr 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 Apr 2026, 23:24 UTC

Earnings

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 Apr 2026, 23:24 UTC

Earnings

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 Apr 2026, 23:24 UTC

Earnings

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 Apr 2026, 23:24 UTC

Earnings

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 Apr 2026, 23:22 UTC

Earnings

China Longyuan 1Q Net CNY1.70B, Down 14%

29 Apr 2026, 23:22 UTC

Earnings

China Longyuan: Power Generation Down 2.9% as of End-March

29 Apr 2026, 23:20 UTC

Earnings

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 Apr 2026, 23:20 UTC

Earnings

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 Apr 2026, 23:19 UTC

Earnings

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 Apr 2026, 23:19 UTC

Earnings

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 Apr 2026, 23:19 UTC

Earnings

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 Apr 2026, 23:19 UTC

Earnings

China Vanke 1Q Loss Narrows>000002.SZ

29 Apr 2026, 23:18 UTC

Earnings

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 Apr 2026, 23:17 UTC

Earnings

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 Apr 2026, 23:15 UTC

Earnings

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 Apr 2026, 23:15 UTC

Earnings

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 Apr 2026, 23:13 UTC

Earnings

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 Apr 2026, 23:12 UTC

Earnings

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 Apr 2026, 23:11 UTC

Earnings

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 Apr 2026, 23:11 UTC

Earnings

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 Apr 2026, 23:04 UTC

Earnings

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 Apr 2026, 23:04 UTC

Earnings

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

-7.35% downside

12 Months Forecast

Average 54.8 USD  -7.35%

High 58 USD

Low 50 USD

Based on 6 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

201 / 348 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat